OB/GYN Clinical Alert – October 1, 2003
October 1, 2003
View Issues
-
Oral Contraceptive Mortality
Vessey, Painter, and Yeates from the University of Oxford used the prospective cohort of women enrolled in the Oxford Family Planning Association Study to assess mortality in users and nonusers of oral contraceptives. -
Management of Port-Site Metastasis After Laparoscopic Surgery for Ovarian Cancer
Port-site metastasis after laparoscopic surgery during chemotherapy, or when adequate chemotherapy has been given, is usually associated with poor outcome. -
Accuracy of Laparoscopic Diagnosis of PID
Compared to histopathology, visual diagnosis of PID is neither accurate nor reproducible. -
Prevention of Breast Cancer with Tamoxifen
Only 5% of white women and 0.6% of black women are potential candidates for tamoxifen chemoprevention. -
Intraperitoneal Radioactive Phosphorus (32P) vs Observation After Negative Second-Look Laparotomy for Stage III Ovarian Carcinoma
Intraperitoneal chromic phosphate did not decrease the risk of relapse or improve survival for patients with stage III epithelial ovarian cancer after a negative second-look surgery. -
Use of OCP’s to Eliminate Withdrawal Bleeding
Daily administration of a low dose oral birth control pill results in significantly fewer bleeding days. -
Death by a Thousand Indignities: The Saga of HRT
This week there were 2 articles in the New England Journal of Medicine that explored the link between postmenopausal hormone use and heart disease. The first article was the final analysis of the Prempro® arm of the WHI. -
Seasonale: A Revolutionary Contraceptive
-
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch: Vardenafil Will Compete for Share of ED Market
The FDA has approved vardenafil (LevitraBayer and GlaxoSmithKline) for the treatment of erectile dysfunction in men. Vardenafil joins sildenafil (Viagra) as the only 2 drugs approved for this indication in this country.